FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * SAMANA CAPITAL, L.P.   2. Issuer Name and Ticker or Trading Symbol IMMUNOGEN INC [IMGN] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 283 GREENWICH AVENUE 3. Date of Earliest Transaction (Month/Day/Year) 07/31/2009 (Street) GREENWICH, CT 06830 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) ___ Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 07/31/2009   S   3,500,000 D $ 8.64 5,525,200 (1) (2) D (1) (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
SAMANA CAPITAL, L.P. 283 GREENWICH AVENUE GREENWICH, CT 06830		X
MORTON HOLDINGS, INC. 283 GREENWICH AVE GREENWICH, CT 06830		X
KORSANT PHILIP B 283 GREENWICH AVE GREENWICH, CT 06830		X

Signatures

SAMANA CAPITAL, L.P., By: Morton Holdings, Inc., its general partner, By: /s/ Catherine O'Dwyer, Vice President of Morton Holdings, Inc.		07/31/2009
**Signature of Reporting Person		Date
MORTON HOLDINGS, INC., By: /s/ Catherine O'Dwyer, Vice President of Morton Holdings, Inc.		07/31/2009
**Signature of Reporting Person		Date
/s/ Philip B. Korsant		07/31/2009
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	This statement is being filed by Samana Capital, L.P. ("Samana Capital"), Morton Holdings, Inc. ("Morton Holdings") and Philip B. Korsant ("Korsant" and collectively with Samana Capital and Morton Holdings, the "Reporting Persons"). Morton Holdings is the general partner of Samana Capital. Korsant is the sole shareholder of Morton Holdings. (Due to SEC formatting limitations, please see continuation in footnote 2)
(2)	(Continued from footnote 1) Samana Capital is the owner of record of all of the shares of ImmunoGen, Inc. common stock, par value $0.01 per share ("Common Stock"), reported above. The Reporting Persons may each be deemed to have or share voting or investment power over 4,312,500 shares of the Common Stock reported in Column 5 above, but do not have or share voting or investment power above the remaining 1,212,700 shares of Common Stock reported in Column 5 above. Each of the Reporting Persons disclaims beneficial ownership of the shares of Common Stock reported herein, except to the extent of its respective pecuniary interests.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.